1.36
Pacific Biosciences Of California Inc stock is traded at $1.36, with a volume of 6.74M.
It is up +0.00% in the last 24 hours and down -17.58% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.36
Open:
$1.36
24h Volume:
6.74M
Relative Volume:
1.07
Market Cap:
$422.42M
Revenue:
$160.03M
Net Income/Loss:
$-128.58M
P/E Ratio:
-3.1865
EPS:
-0.4268
Net Cash Flow:
$-121.21M
1W Performance:
+0.00%
1M Performance:
-17.58%
6M Performance:
-47.08%
1Y Performance:
-11.69%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PACB
Pacific Biosciences Of California Inc
|
1.36 | 422.42M | 160.03M | -128.58M | -121.21M | -0.4268 |
|
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacific Biosciences of California, Inc. Revenue Breakdown – NASDAQ:PACB - TradingView
PACB|Pacific Biosciences of California Inc|Price:1.360|Chg%:-0.040 - TradingKey
Pacific Biosciences of California Inc - TradingKey
TradingKey - TradingKey
PACB|Pacific Biosciences of California Inc|Price:1.360| - TradingKey
Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacific Biosciences of California Inc (PACB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pacific Biosciences of California Inc (PACB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PACB stock reflects Illumina merger plan as investors weigh 2025 revenue outlook - Ad-hoc-news.de
Pacific Biosciences of California offers expert guidance for targeted sequencing applications - Traders Union
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market - Yahoo Finance
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 - Moomoo
PacBio’s next earnings update will stream live Aug. 5 - Stock Titan
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Pacific Biosciences of California launches Rapid HiFi WGS Resource Bundle to accelerate genomic research - Traders Union
Pacific Biosciences (PACB) Proxy filing Summary - Quartr
Pacific Biosciences of California launches multi-use SMRT Cell for affordable high-quality WGS - Traders Union
Pacific Biosciences of California (PACB) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Pacific Biosciences Announces Resignation of Board Member - TipRanks
Pacific director Christopher M. Smith resigns from board - TradingView
[8-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Reports Material Event - Stock Titan
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth - TradingView
Pacific Biosciences of California opens registration for webinar on SPRQ-Nx chemistry driving efficiency gains - Traders Union
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences (PACB) Stephens Annual Investment Conference Summary - Quartr
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Yahoo Finance
Pacific Biosciences updates its sequencing strategy. Investors watch long-read technology - ad-hoc-news.de
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Is Pacific Biosciences (PACB) The Best Rising Penny Stock? - Insider Monkey
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Attendance surges at Pacific Biosciences of California charity run, boosting genetic testing support - Traders Union
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2500 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2000 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000E Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000 Growth Benchmark - marketscreener.com
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions - Yahoo Finance
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California, Inc. Actuals & Estimates (NASDAQ:PACB) - TradingView
PACIFIC BIOSCIENCES OF CALIFORNIA ROE % Adjusted to Book Val - GuruFocus
Enterprise value to revenue forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
PACB Forecast — Price Target — Prediction for 2027 - TradingView
PACB Stock Gains Focus As New Sequencing Tech Slashes Genome Costs - StocksToTrade
Price to book forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California launches kit to streamline high-throughput sequencing operations - Traders Union
Price to sales forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Price to earnings forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Enterprise value to EBITDA forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):